EQT Life Sciences leads EUR 93 million oversubscribed Series A round in PanTera, which aims to accelerate global actinium - 225 production

Contributed by: PR Newswire

Tags

EQT-Pantera

More Like This

EQT Life Sciences leads USD 75 million Series B in Atalanta Therapeutics, a biotech firm developing treatments for epilepsy and Huntington's disease

PR Newswire associated0

IONETIX Corporation and AlfaRim Medical B.V. announce a strategic partnership to fast-track commercial production of Actinium-225

PR Newswire associated0

Blue Earth Therapeutics Ltd announces completion of $76.5M Series A financing to accelerate development of next generation targeted radioligand therapies

PR Newswire associated0

AtomVie Global Radiopharma and TerraPower Isotopes Announce Strategic Supply Agreement for Actinium-225 to Advance Radiopharmaceutical Development and Manufacturing

PR Newswire associated0

ARTBIO Raises Oversubscribed and Upsized $90 Million Series A Financing to Progress Pipeline and Isotope Technology Development for New Class of Alpha Radioligand Therapies

EQT Life Sciences leads €54 Million Series A Financing of ATB Therapeutics

Arctic Therapeutics Announces €26.5M Oversubscribed Series A Financing

Blue Earth Therapeutics Ltd Announces Expansion of Partnership With Seibersdorf Labor GmbH to Include Manufacture of Therapeutic Radiopharmaceutical, 225Ac-rhPSMA-10.1